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This study aimed to evaluate whether patients with advanced non-small-cell lung cancer experience disrupted rest–activity daily
rhythms, poor sleep quality, weakness, and maintain attributes that are linked to circadian function such as fatigue. This report
describes the rest–activity patterns of 33 non-small-cell lung cancer patients who participated in a randomised clinical trial evaluating
the benefits of melatonin. Data are reported on circadian function, health-related quality of life (QoL), subjective sleep quality, and
anxiety/depression levels prior to randomisation and treatment. Actigraphy data, an objective measure of circadian function,
demonstrated that patients’ rest–activity circadian function differs significantly from control subjects. Our patients reported poor
sleep quality and high levels of fatigue. Ferrans and Powers QoL Index instrument found a high level of dissatisfaction with health-
related QoL. Data from the European Organization for Research and Treatment for Cancer reported poor capacity to fulfil the
activities of daily living. Patients studied in the hospital during or near chemotherapy had significantly more abnormal circadian
function than those studied in the ambulatory setting. Our data indicate that measurement of circadian sleep/activity dynamics should
be accomplished in the outpatient/home setting for a minimum of 4–7 circadian cycles to assure that they are most representative of
the patients’ true condition. We conclude that the daily sleep/activity patterns of patients with advanced lung cancer are disturbed.
These are accompanied by marked disruption of QoL and function. These data argue for investigating how much of this poor
functioning and QoL are actually caused by this circadian disruption, and, whether behavioural, light-based, and or pharmacologic
strategies to correct the circadian/sleep activity patterns can improve function and QoL.
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Every cell in our body has oscillators involved in the sending and
receiving of signals that regulate the physiological economy of the
body. Many of these oscillators have a circadian period, and their
synchronisation integrates the many physiological and behavioural
processes required to meet the challenges of daily life (Mormont
and Levi, 2003).
The experimental destruction of an animal’s rest–activity
rhythms accelerates tumour growth, while restoring normal
circadian function enhances the survival benefits of chemotherapy
(Filipski et al, 2003). However, there has been surprisingly little
data collected on the circadian function of cancer patients. What
little is known confirms the preclinical data that links distorted
circadian function with accelerated tumour progression. Hrush-
esky et al (1985) first documented abnormal circadian patterns
among cancer patients. Mormont et al (2000) found that a
flattened rest–activity circadian rhythm in metastatic colon cancer
patients was an independent predictor for treatment failure and
premature death. Similarly, an abnormally flat circadian cortisol
rhythm in metastatic breast cancer patients was an independent
predictor of survival (Sephton et al, 2000).
Although direct measurements of circadian function in cancer
patients are sparse, data on behaviours or symptoms linked to
disrupted circadian function, such as sleep quality and fatigue, is
relatively extensive. For example, the subjective sleep quality of
cancer patients approaches levels found in insomniacs (Silberfarb
et al, 1993; Mormont and Waterhouse, 2002; Sephton and Spiegel,
2003). Consequently, disturbances in sleep patterns may account
for many of the symptoms that plague cancer patients – fatigue
and decreased immune function – as well as emotional problems
such as irritability, depression and decreased pleasure in work and
social activities (Sheely, 1996).
Fatigue is linked to disrupted sleep rhythms and the prevalence
of fatigue rises to over 80% in patients undergoing chemotherapy
(Lee et al, 2004). Indeed, approximately 50–75% of cancer patients
have fatigue levels that impair health-related quality of life (QoL)
at diagnosis. Consequently, it is not surprising that treatment-
related fatigue is not necessarily ameliorated by erythropoietin
agents and aerobic exercise.
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a disrupted circadian/sleep functions and many of the symptoms
that degrade the patients’ QoL. It is uncertain whether cancer
treatment affects circadian function (Lee et al, 2004). There is
emerging evidence that suggests cancer patients are at high risk for
problems associated with disrupted circadian function; poor sleep
quality, fatigue, and decreased QoL.
During the past several years, a series of treatment innovations
have promised to significantly prolong the survival of cancer
patients. For example, the introduction of platinum compounds
into the treatment of advanced non-small-cell lung cancer
(NSCLC) has significantly prolonged survival of patients who are
either refractory to, or relapse following first-line chemotherapy
(Evans, 2004). None of these protocols, however, have exploited
the circadian rhythms that regulate the timing of gene activity
and cell function. Today, investigators have discovered that the
rest/activity cycle is a reliable marker of the circadian system
(Mormont and Levi, 2003). There is accumulating preclinical and
clinical evidence that patients with advanced cancer placed on
chronotherapeutic protocols have significantly longer lifespan,
higher QoL scores and experience fewer and less-intense
symptoms (Mormont et al, 2000).
The chronobiotic, clock-resetting agent and sleep-facilitating
hormone melatonin plays a significant role in the synchronisation
of the sleep/wake cycle. Distortions in the production or release
of melatonin have been linked to a variety of symptoms such
as insomnia and daytime drowsiness (Haimov and Lavie, 1997).
Others have shown that diminished circadian amplitudes and
dampened night time melatonin release characterise the melatonin
circadian dynamics of patients with cancer (Lewy et al, 1980;
Danforth et al, 1985; Bartsch et al, 1992). Lewy has repeatedly
demonstrated the capacity of orally administered melatonin to
reset the circadian clock (Lewy et al, 1999). The medical literature
reports that melatonin produces a variety of favourable outcomes
in oncology patients. Lissoni’s group reports that melatonin
reduces the toxicity of various chemotherapeutic agents, including
Cisplatin, Etoposide, Anthracyclines, and 5-Flourouracil. They
found a statistically significant reduction in treatment-related
adverse events, such as myelosuppression, neurotoxicity, nephro-
toxicity, cardiotoxicity, and asthenia (Lissoni et al, 1992, 1994,
1997, 1999).
We have designed a multicentre trial to evaluate the chron-
otherapeutic role of melatonin in the treatment of stage III and IV
NSCLC and to analyse the relationships between circadian
function, fatigue, insomnia and overall QoL. This interim analysis
evaluated the circadian function, sleep quality, and levels of fatigue
prior to treatment of the first 33 study patients. These data are the
initial step in evaluating the chronotherapeutic role of melatonin
in patients with advanced lung cancer.
PATIENTS AND METHODS
Patients
The study was conducted at Cancer Treatment Centers of America
at Midwestern Regional Medical Center (MRMC) and WJB Dorn
Veterans Affairs Medical Center (VAMC). Patients, between the
ages of 18 and 80 years, who had a pathologically confirmed
diagnosis of Stage IIIA, IIIB–IV NSCLC, bidimensionally measur-
able disease and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0, 1, and 2 were included. Patients who
had failed chemotherapy were acceptable. Ineligible patients had
medical conditions that precluded the administration of chemo-
therapeutic agents such as inadequate renal function with serum
creatinine 4221mmoll
 1, inadequate hepatic function
with bilirubin 434.2mmoll
 1, severe uncontrolled heart failure,
hypertension, arrhythmia, angina, lung disease, meningeal carci-
nomatsis, uncontrolled infection, and uncontrolled brain metas-
tases. The patients signed an Informed Consent indicating that
they were aware of the investigational nature of the study and the
randomised study design. Institutional Review Boards at MRMC
and VAMC approved this study.
Procedures and summary of measurement tools
Actigraphy measurements of rest–activity cycles A watch-like
wrist actigraph (Ambulatory Monitoring, Inc., AMI), worn on the
nondominant wrist, was used to record a patient’s movement
pattern over a 4–7-day period (Hauri and Wisbey, 1992; Hilliker
et al, 1992). Patients at VAMC had all activity measurements
performed in the week prior to therapy in the ambulatory/home
setting. Owing to the tertiary referral nature of the MRMC base,
actigraphy was performed immediately before or during and
immediately following the first three chemotherapy cycles.
Midwestern Regional Medical Center patients were inpatients
during this measurement span.
The Pittsburgh Sleep Quality Index (PSQI) The PSQI is a self-
reported questionnaire that measures sleep quality and quantity
over a 1-month period. The PSQI contains 19 items that comprise
an overall sleep score, and it produces separate component scores
in seven areas: subjective sleep quality, sleep latency, sleep
duration, habitual sleep efficiency, sleep disturbances, use of
sleeping medication, and daytime dysfunction. The component
scores are combined to produce the Global Sleep Quality Score
ranging from 0 to 27.
The European Organization for Research and Treatment of Cancer
Quality of Life Core Questionnaire (EORTC QLQ-C30) The
EORTC QLQ-C30 was developed to measure a patient’s capacity
to fulfil the activities of daily life at the workplace and at home.
Five function scales measure physical, role, emotional, social, and
cognitive function, and three symptom scales measure fatigue,
nausea, and pain. There is one global health/overall QoL scale and
six single questions on symptoms and financial difficulties. All
scores range from 0 to 100. High scores on overall QoL and the five
functioning scales imply normal or unlimited function, whereas
high scores on the symptom scales imply higher, more intense
symptoms.
To interpret the clinical significance of the scores, we
characterised differences from the normal population as large,
moderate, or small according to data from Osoba et al, who
obtained data from patient interviews. This research reported that
a small change for the better or worse followed a shift of 5–10
points, while a 20-point increment or decrement in score reflected
a large change in patients’ QoL (Osoba et al, 1998).
Ferrans and Powers QoL Index (QLI) The QLI is a self-reported
questionnaire that measures QoL based on a patient’s level of
satisfaction with respect to various aspects of life, and the
importance of certain aspects in his/her life. We used Cancer
Version III, which asks the patient to rate satisfaction with such
aspects of life as health, energy, personal relationships, and
physical functioning. This version also asks the patient to rate the
importance of aspects such as health, pain, independence, and
personal relationships. The scores range from 0 to 30, with higher
scores indicating greater satisfaction with life.
Statistical analysis
Descriptive statistics such as mean and standard error were
computed for numeric demographic factors, Sleep Index, and QoL
scores. Either analysis of variance or the nonparametric counter-
part, Kruskall–Wallis test, whichever was appropriate was used to
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implemented in SAS v.2 (Cary, NC, USA).
A detailed description of the actigraphy measurement has been
included in Appendix I. Owing to the differences in the setting of
actigraphy monitoring between centres, outpatient/home, prior to
chemotherapy in VAMC vs in-patient and during chemotherapy
for MRMC/Zion, all analyses were performed such that centre
differences were not ignored.
RESULTS
Patient characteristics
There were systematic differences in demographic and clinical
variables in study participants by site. The MRMC site patients
were younger than VAMC (56.71 vs 71.75, years, respectively;
t¼4.39 Po0.01) and higher proportion of the MRMC patients had
prior chemotherapy than VAMC (14 of 21 vs four of 12,
respectively; w
2¼3.42, P¼0.06). Of the 21 MRMC patients, 12
were female patients, while VAMC only treated males (w
2¼10.77,
Po0.01). A significantly higher proportion of MRMC patients had
stage IV (80%) disease than VAMC (20%) (w
2¼5.87, P¼0.02).
Finally, MRMC collected actigraphy data during chemotherapy in
hospitalised patients, while VAMC data were collected at the
patient’s home prior to chemotherapy.
Sleep and activity patterns
Actigraphy data Table 1 summarises the actigraphy data during
putative daily wake spans and compares 33 cancer patients with a
reference population of 35 normal adults. In the absence of
available actigraphy database of gender and age-matched indivi-
duals, we considered the actigraphy database generated by
Ambulatory Monitoring Inc., 2002 as our reference population.
These data were obtained from a heterogenous group of 35 adults,
who were 20–50 years old, who worn actigraphs for 3 days on the
average and had no known disease or chronic condition. We found
that in all parameters, cancer patients were significantly different
than the reference population. Table 2 depicts actigraphy data
during putative daily sleep spans. As during the wake span, the
cancer patients differed from the reference population in all
parameters. In both wake and sleep cycles and for all parameters,
cancer patients actigraphy data indicate fractured and disrupted
circadian function.
Differences in actigraphy baseline data by site There were
significant differences in actigraphy results by site. Actigraphy
data were recorded and obtained in the in-patient setting at
MRMC, while obtained in the patients’ home for VAMC patients.
Consequently, a simultaneous comparison of circadian parameters
(Bingham test) found that the average circadian rhythms of
patients at both sites were significantly different (F¼16.86,
Po0.01). For example, VAMC patients had higher circadian
amplitudes, indicating more robust rhythms (F¼4.46, P¼0.04).
WJB Dorn Veterans Affairs Medical Center patients were more
active as indicated by their higher peak activity (F¼4.84,
P¼0.036). Also, the day–night activity difference was greater in
VAMC patients as indicated by the higher IoO (90.072.2 vs
78.972.4). They also had more stable circadian rhythm pattern as
exhibited by the higher mean 24-h autocorrelations (F¼5.41,
P¼0.029).
Pittsburgh Sleep Quality Index Data from each PSQI showed that
the lung cancer patients scored consistently higher than a control
group in all seven-component scores. Consequently, the mean
Global Sleep Quality Score for the study population is 10.6, which is
more than 2.0 points from the 48 score and much higher than the
score of 5 that identifies poor sleep quality in cancer-free
individuals (Carpenter and Andrykowski, 1998) (Table 3).
While there was no statistically significant difference by site for
the Global Sleep Quality, there were statistically significant
differences in two of the seven components of the PSQI. Sleep
quality was statistically significantly better among veteran patients
at VAMC (1.570.20) than MRMC patients (2.370.3; F¼5.60,
P¼0.025). Moreover, MRMC patients used more sleep medica-
tions than VAMC (F¼5.88, P¼0.022).
Quality of life
Patients with advanced NSCLC reported lower scores for all
EORTC-QLQ-C30 domains when compared to population-based
controls (Table 4).
Despite the differences in the sites by patients’ age and clinical
history, there were few differences in the EORTC instrument
scores. Nonetheless, VAMC showed a statistically significant lower
physical function, 47.3 compared to MRMC’s 69.5 (Po0.001),
which may reflect that VAMC patients were older. In addition,
there was a 22-point difference in the Dyspnoea item, 38.1 for
MRMC compared to 60.6 for VAMC (Po0.014). This indicates that
Table 1 Sleep and activity during putative daily wake span
Sleep and activity variable
Cancer
patients
(n¼33)
Reference
population
(n¼35)
Mean daily activity (min) 92.875.63 127717.11
Mean activity during wakefulness (min) 117.577.11 182.6725.08
Mean duration of sleep during wakefulness (min) 195.0725.03 46.5741.05
% of wakefulness spent sleeping 21.872.93 4.773.92
Number of sleep episodes during wakefulness 17.871.82 5.475.06
Table 2 Sleep and activity during putative daily sleep span
Mean and standard error
Sleep and activity variable
Cancer
patients
(n¼33)
Reference
population
(n¼35)
Frequency of long naps 9.571.08 2.171.96
Duration of wakefulness during night sleep (min) 134.1714.94 31.1721.53
Number of sleep interruptions nightly 14.671.35 6.974.52
% of sleep span actually spent sleeping 71.273.09 93.074.88
Nightly average duration of long sleeps (min) 112.5713.22 225.67100.8
Table 3 Pittsburgh Sleep Quality Index (PSQI) (N¼33)
Study
population
Healthy
controls
a
Sleep indicators Mean7s.e. Mean7s.e.
Sleep quality 1.770.18 0.3570.07
Sleep latency 1.670.22 0.5670.10
Sleep duration 1.370.22 0.2970.07
Sleep efficiency 1.370.24 0.170.04
Sleep disturbance 2.370.12 1.070.05
Sleep medication 0.970.19 0.0470.04
Daytime dysfunction 1.570.27 0.3570.07
Global sleep quality score 10.670.95 2.6770.23
aOwen et al (1999) 26, 1649–1651.
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pared to MRMC patients.
Table 5 reports the results from the Ferrans and Powers QLI,
and compares the mean scores of the study population with
population-based data provided by Ferrans. MRMC patients’ score
of 12.5 was statistically significantly lower than the VAMC score of
18.7 (P¼0.04). Interestingly, MRMC patients’ capability of
completing the physical activities of daily life was statistically
significantly higher in the EORTC physical domain, but their
dissatisfaction with their capacity to fulfil the activities of daily
living was much higher than the VAMC patients.
Circadian function and QoL outcomes by performance
status
In NSCLC, patients with a PS 2 have a much poorer prognosis and
experience lower rates of tumour response to therapy than patients
with PS of 0 and 1 (Hoang et al, 2005).
Several circadian sleep/wake parameters were computed in
order to assess and compare sleep characteristics of patients with
different Performance Status. The mean duration of long sleep
episodes fell from 129min for patients with PS 0–96.5min in PS 2
patients (Po0.05). This indicates that patients with poor
performance status (PS 2) tend to have more disturbed sleep
during the night. These long sleep spans, however, are short
compared to those of normal adults, which average 225min.
Similarly, the mean duration of activity during wakefulness was
unaffected by PS score; however, patients with PS 2 tend to be less
active than patients with PS 1. In the normal population, the
duration of mean activity during wakefulness was 182.6min, which
is nearly 60min longer than our PS 0 patients. Although the
number of sleep interruptions nightly was not statistically
significant among PS levels, there were more sleep interruptions
in patients with poor PS compared to those with good PS (Table 6).
We evaluated several Cosinor parameters such as circadian
amplitude, circadian fragmentation/amplitude of ultradian
rhythms, circadian quotient, peak activity, activity/rest dichotomy
(IoO), rhythm quotient to measure the relationship between
circadian function and PS. The only circadian function that was
statistically significant different in this small sample was the
frequency of ultradian/4-h rhythms (P¼0.046). Higher 4-h
amplitudes indicate disruption of circadian rhythm, which
normally has one peak.
The circadian quotient, which provides a measure of the
strength of the circadian rhythm, compared to other components,
suggests that circadian rhythms are more pronounced in patients
with PS 0 or 1 than patients with PS 2. Daily activity of normal
people usually has one or two circadian peaks, with best cosine fit
at 24 or 12 or 12 and 24h. The rhythm quotient provides a basis for
assessment of the degree of activity/sleep consolidation within
each day. Higher circadian rhythm quotient indicates a more
pronounced circadian rhythm and lower values indicate a
fractured circadian sleep/activity patterns. From Table 6, it is
known that rhythm quotient has an inverse relationship to PS
levels. This indicates that patients with scores of 0 or 1 have less
fractured circadian sleep activity patterns. Furthermore, 24-h
autocorrelations (r24) are higher in patients with PS 0, although not
statistically significant, indicating more pronounced and repro-
ducible day-to-day circadian activity rhythm.
Table 4 EORTC QLQ-C30 – quality of life (N¼33)
Domain
Study
data
mean
Population-
based survey
data mean
Difference
in mean
scores
a
EORTC data
on advanced
non-small-
cell lung
cancer
Functioning scales
Physical function 64.2 89.9  25.7 64.6
Role function 54.8 83.3  28.5 67.2
Emotional function 50 82.8  32.8 67.2
Social function 51 85.8  34.8 70.1
Cognitive function 72.8 86.5  13.7 82.7
Overall QLI 45.5 75.3  29.8 57
Symptom scales
Fatigue scale 53 28.8 24.2 42.5
Nausea 13.8 4 9.8 12.5
Pain scale 59 20.5 38.5 30.5
Single items
Dyspnoea 45.7 14.3 31.4 41
Insomnia 42.8 20.4 22.4 33
Appetite loss 36.2 7.5 28.7 35.4
Constipation 32.4 10.4 22 23.3
Diarrhoea 9.5 9.4 0.1 4.7
Financial difficulties 40.2 9 31.2 13.6
aDifference between Study patients and population-based survey data.
Table 5 Ferrans and Powers QLI (N¼33)
Domain
Study
population –
mean scores
Population-
based mean
scores (std)
Difference in
mean scores
Health/function 15.36 23.19 (4.47)  7.83
Social and economic 22.06 21.83 (4.11) 0.23
Psychological/spiritual 21.4 22.95 (5.21)  1.55
Family 24.08 25.60 (4.49)  1.52
Overall quality of life
score
19.65 23.00 (4.04)  3.35
Table 6 Actigraphy data
Variable Performance status 0 Performance status 1 Performance status 2
Mean activity during wakefulness 123.92719.84 114.3879.13 118.61713.21
Number of sleep interruptions 7.4971.34 9.0971.31 11.572.82
Nightly average duration of long sleep 128.99726.15 112.24720.36 96.52720.36
Rhythm parameters
24-h amplitude 54.17710.05 47.5873.45 42.9974.40
Amplitude of 4-h cosine fit 8.1171.46 7.8671.05 12.8671.86
Circadian quotient 0.5570.08 0.5370.04 0.4770.06
Rhythm quotient 1.0570.16 1.0270.09 0.9470.16
24-h autocorrelation 0.3170.06 0.1770.04 0.2170.05
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(EORTC-QLQ-C30) scores by PS. In all domains, patients with a
PS of 0 scored over 20 points higher than the patients with PS
score of 2 (Figure 1). Moreover, there were greater than 10 points
differences in the physical, role, and emotional domains between
PS 0 and 1 patients. Finally, there was a significant difference
between the near normal fatigue score of 36.5175.8 in PS 0, and
the PS 1 and PS 2 scores of 54.977.8 and 70.8379.6, respectively
(Fc¼3.70, P¼0.037). All of these scores are high and, they
increase with increasing PS scores.
The second QoL instrument, the QLI, also detected differences
by performance status scores. PS 0 patients had scores that were at
least 1.9 points higher than patients with PS scores of 1 or 2 in all
domains of the QLI instrument. Indeed, patients with PS score of 0
scored over six points higher in the Health/Functioning domain
than patients with PS scores of 0 and 1 (Figure 2). Overall, PS 2
experience more intense symptoms, more difficulties in meeting
the challenges of daily life, and express higher levels of
dissatisfaction with Health Function.
DISCUSSION
Non-small-lung cancer patients were recruited on a clinical trial
that investigates whether exogenous melatonin at the appropriate
circadian time improves health-related QoL, diminishes patient
fatigue, and enhances sleep quality and quantity, by a statistically
significant level. We report our analysis of the baseline status of
the initial 33 trial participants to determine whether patients with
advanced NSCLC have distorted circadian rhythms, poor sleep
quality, and compromised QoL. We did this analysis because there
is little data in the clinical literature on the circadian function of
EORTC domains
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Figure 1 EORTC-QLQ-C30 domain scores by ECOG performance status.
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Figure 2 Quality of Life Index domain scores by ECOG performance status.
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(Hrushesky et al, 1985; Mormont et al, 2000). Moreover, the
literature has even fewer data on the relationships between
circadian function, PS, and QoL.
Our analysis found that patients with advanced NSCLC have
distorted circadian rhythms. Trial participants experienced higher
than expected levels of wakefulness during the normal sleep period
and surprisingly extensive sleep periods during normal times
for activity. The patients, for example, spent 71.2% of the putative
sleep time ‘sleeping’, while a ‘normal person’ spends 93% of the
putative sleep time ‘sleeping’. Conversely, these good PS cancer
patients were sleeping 21.8% during the putative wakefulness time,
while normal people spend only 4.7% of the day completely
inactive. All other actigraphy data items confirm this pattern of
excess rest during the activity phase of the circadian cycle and
increased activity during the rest phase of the daily cycle of sleep
and activity. Cosinor analysis shows clearly that our patients’
circadian rhythm function is significantly different from normal
persons. However, because of the obvious age and gender
differences between our patient cohorts and the reference
population, we need age and gender-matched comparison to
adequately evaluate the circadian patterns of our patient
population.
Curiously, there was no correlation between a patients’ PS score
and any Actigraphy data item. PS is the most useful stratification
variable for predicting patient response and survival (Karnofsky
et al, 1948). For example, the potential lifespan of a PS 2 patient is
considerably shorter than that of a patient with a PS of 1. The
actigraphy data indicated that the occurrence of a stage III or IV,
pretreated or newly diagnosed, produces severe significant
impairment in the patient’s circadian function. A circadian rhythm
has a 24h period. Cosinor analysis revealed that circadian rhythms
of patients with PS 2 were more distorted than those of patients
with a PS 0 or 1. Consequently, patients with more advanced
disease experience a greater disruption in their circadian rest/
activity cycle.
As expected, sleep quality data from the PSQI confirms the
actigraphy data. Patients’ PSQI Global Sleep Quality Score of 10.6
is well above the threshold level of five for poor sleep quality. With
the exception of daytime dysfunction, the sleep instrument found
no statistical differences by performance status scores. Conse-
quently, both the actigraphy and PSQI reveal that patients with
advanced NSCLC irrespective of their treatment history have very
poor sleep quality. More importantly, the very poor sleep quality of
these patients was independent of the patients’ PS score. This
means that, by the time advanced lung cancer patients present for
therapy, their circadian organisation has been greatly disturbed.
Clinical research among noncancer patients has linked poor
sleep quality with lower scores in instruments measuring health-
related quality of life. The self-report of QoL among participants
of this trial were significantly lower than the general population.
The mean scores for the EORTC functional domains, with the
exception of the cognitive domain, were over 20 points less than
those reported in population-based surveys. Moreover, in the
EORTC symptom items, our trial participants reported greater
than 20-point increase (worse symptoms) in a variety of EORTC
symptom items (pain, fatigue, dyspnoea, insomnia). These data
make it clear that the trial participants’ ability to fulfil the activities
of daily life is much lower than that of the general population.
The EORTC instrument emphasises the patients’ capacity to
perform the activities of daily living, but the QLI evaluates the
patients’ degree of satisfaction with their QoL. The trial
participants’ Health and Function domain score is at the bottom
quintile of the general population. Thus, our patients are
expressing a high degree of dissatisfaction with their capacity to
fulfil the activities of daily life. Interestingly, despite the difficulties
the trial patients were experiencing in meeting the challenges of
daily living, they still expressed satisfaction with key aspects of life
– social and economic, psychological and spiritual, and family that
is similar to the general population.
Unlike the actigraphy and PSQI data, the PS scores stratified the
QoL results. The EORTC functional domains scores were highest
in patients with a PS 0 status and lowest in PS 2. Moreover, the
symptom items tended to increase with increasing PS scores and
the fatigue scores for PS 2 patients were twice the scores reported
by PS 0 patients. The QLI instrument separated patients with PS 0
but did not differentiate PS 1 and 2 patients.
Significant differences between the two study sites were
observed in almost all of the circadian parameters. We attribute
this to the different millieux when actigraphy is measured.
Actigraphy was obtained in VAMC patients in the ambulatory/
home setting prior to therapy and in hospital during chemother-
apy in MRMC patients. As a result, the MRMC patients might
have been more sedentary than usual. Circadian rhythms of
patients in MRMC are less robust, day–night activity difference is
less pronounced. Further, day-to-day rhythm of VAMC patients is
more stable compared to MRMC, indicated by the 24-h
autocorrelation.
In summary, patients with advanced NSCLC have distorted
circadian function independent of their PS. Indeed, the develop-
ment of an advanced NSCLC is accompanied by very unsubtle
distortions in an individual’s circadian function. Moreover, the
patients exhibit the attributes of individuals suffering from
disrupted circadian function – complaints of poor sleep quality,
fatigue, and insomnia. We also documented the superiority of
outpatient/home as opposed to inpatient actigraphy for most
accurately measuring and assessing the circadian organisation of
cancer patients.
Several limitations of this study require careful acknowledg-
ment. This interim analysis suffers from relatively small sample
size. Our sample size is not enough to accommodate the number of
comparisons made within this study. There were clear demo-
graphic and clinical differences between the two populations
recruited at the two participating cancer centres making our
overall study population a little heterogeneous. Lastly, we lacked
adequate age- and gender-matched comparisons to clearly evaluate
the extent of distortions in circadian function of our cancer
patients. Despite these limitations, we believe that the participants
of this trial are appropriate subjects to investigate whether
exogenous melatonin administered chronotherapeutically can
restore patient circadian function, improve sleep quality, health-
related quality of life, and survival.
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Appendix I
The following parameters described the activity phase of the daily
circadian cycle: mean daily activity, mean duration of activity
during wakefulness, mean duration of sleep during wakefulness,
proportion of wakefulness spent sleeping, number of sleep
episodes during wakefulness, and frequency of long naps. During
the presumed sleep phase of the circadian cycle, the following
parameters were evaluated: mean duration of wakefulness, number
of sleep interruptions, proportion of sleep episode spent actually
sleeping, and frequency of long duration of sleep.
The number of accelerations per minute for a continuous 4–7
days was recorded through the actigraphy watch and was
translated into sleep/activity parameters through the Act Millen-
nium and Action W2 software (Ambulatory Monitoring, Inc.).
Rhythmometric analysis (using Chronolab v2) was carried out on
these sleep/activity patterns in order to assess disruption and
consolidation of sleep in lung cancer patients. Rhythmometric
analysis fits a cosine curve to the circadian activity providing three
standard parameters: mesor – the average activity over the 24-h
period, amplitude-peak to nadir difference and acrophase – the
time of peak activity. In addition to these parameters, peak activity
(mesorþamplitude) to measure activity levels, the circadian
quotient (amplitude/mesor) to characterise the strength of the
circadian rhythm, and the rhythm quotient (A24h/(A4þA8þA12))
were computed. Higher amplitudes indicate more robust rhythms
but people who move vigorously would have higher amplitude,
thus, the circadian quotient provides normalised values that would
allow comparison between individuals (Satlin et al, 1991; Ancoli-
Israel et al, 1997). We also looked at the dichotomy index (IoO),
comparing amounts of activity when in bed and out of bed, which
is significantly associated with colorectal cancer patients’ quality of
life and survival (Mormont et al, 2000). IoO is the percentage of
minutes or epochs during the putative sleep span with activity
score that are less than the median activity during the putative
wakefulness. Thus, high IoO reflects a marked rest/activity
rhythm (Mormont et al, 2000). Further, circadian rhythms were
assessed through spectral density analysis where 24-h autocorrela-
tions (r24) were computed. Autocorrelations theoretically can
range from  1t oþ1. If a circadian variation is present,
autocorrelations will increase around 24h and a more pronounced
and stable day-to-day circadian rhythm will result in a higher
autocorrelation at 24h.
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